Why do different agents with the same targets not perform with the same results in the clinic?
Finding the sweet spot between safety and activity
When CAR-T and bispecifics create a crowded competitive landscape
An early stage landscape to watch out for with key changes happening in 2024
It's time to start pointing the way for new directions in the Menin niche
It's time to look to the future beyond plain vanilla ADCs
Next generation CAR-T cells are coming to the clinic in 2024
Improving T cell fitness is an important goal for researchers in 2024
The Yin and Yang of NK and T cells and how this can impact therapies
What was generating interest from Pharmaland in the ASH poster halls?
What to watch for in emerging CAR-T cell therapy approaches and how they may give antibodies a run for their money
10 IO topics to watch out for at ASH23
In our latest Preview from the American Society of Hematology, we’re using the dragon’s…
How a competitive landscape can change drastically over a short time
What's next beyond BTK inhibition in lymphomas and CLL?
Pulling disparate sources together to develop a more optimised approach to targeting oncoproteins
A look at the potential missing piece in making bispecifics even better
Will in vivo CAR-T cell therapies go prime time?
From CAR-T cells to protein degradation
Do we need to pay more attention to the underlying biology in aggressive lymphomas?
Early-stage agents in development for multiple myeloma - hit or miss?
Challenges and opportunities in the myeloma niche
